Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design

In Parkinson's disease (PD), gait and balance is impaired, relatively resistant to available treatment and associated with falls and disability. Predictive models of ambulatory progression could enhance understanding of gait/balance disturbances and aid in trial design. To predict trajectories...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Movement disorders 2023-10, Vol.38 (10), p.1774-1785
Hauptverfasser: Venuto, Charles S, Smith, Greta, Herbst, Konnor, Zielinski, Robert, Yung, Norman C W, Grosset, Donald G, Dorsey, E Ray, Kieburtz, Karl
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1785
container_issue 10
container_start_page 1774
container_title Movement disorders
container_volume 38
creator Venuto, Charles S
Smith, Greta
Herbst, Konnor
Zielinski, Robert
Yung, Norman C W
Grosset, Donald G
Dorsey, E Ray
Kieburtz, Karl
description In Parkinson's disease (PD), gait and balance is impaired, relatively resistant to available treatment and associated with falls and disability. Predictive models of ambulatory progression could enhance understanding of gait/balance disturbances and aid in trial design. To predict trajectories of ambulatory abilities from baseline clinical data in early PD, relate trajectories to clinical milestones, compare biomarkers, and evaluate trajectories for enrichment of clinical trials. Data from two multicenter, longitudinal, observational studies were used for model training (Tracking Parkinson's, n = 1598) and external testing (Parkinson's Progression Markers Initiative, n = 407). Models were trained and validated to predict individuals as having a "Progressive" or "Stable" trajectory based on changes of ambulatory capacity scores from the Movement Disorders Society Unified Parkinson's Disease Rating Scale parts II and III. Survival analyses compared time-to-clinical milestones and trial outcomes between predicted trajectories. On external evaluation, a support vector machine model predicted Progressive trajectories using baseline clinical data with an accuracy, weighted-F1 (proportionally weighted harmonic mean of precision and sensitivity), and sensitivity/specificity of 0.735, 0.799, and 0.688/0.739, respectively. Over 4 years, the predicted Progressive trajectory was more likely to experience impaired balance, loss of independence, impaired function and cognition. Baseline dopamine transporter imaging and select biomarkers of neurodegeneration were significantly different between predicted trajectory groups. For an 18-month, randomized (1:1) clinical trial, sample size savings up to 30% were possible when enrollment was enriched for the Progressive trajectory versus no enrichment. It is possible to predict ambulatory abilities from clinical data that are associated with meaningful outcomes in people with early PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
doi_str_mv 10.1002/mds.29519
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10615710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2882215264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c364t-d600520960c4a9121a1a6e925473266481c9541457e969519ebc13863d2a81f63</originalsourceid><addsrcrecordid>eNpdkU1PGzEQhq2KqgTaQ_9AZYlDQWKpx157vScUQr8kpOZAz5bjdYLDrh08u5XCr2dTKIKe5jCPXr0zDyEfgZ0BY_xL1-AZryXUb8gEpIBCc1ntkQnTWhYCtNwnB4hrxgAkqHdkX1RCCQ1yQtbz7Jvg-hBXdNothtb2KW_pzG6sC_2WhkjnNt-GiCl-RnoZ0Fv0tE90Gm27vfd0ntMqe8SQ4im9CKkbcZ_xlNrY0OscbEsvPYZVfE_eLm2L_sPTPCS_v329nv0orn59_zmbXhVOqLIvGsWY5KxWzJW2Bg4WrPI1l2UluFKlBlfLEkpZ-VrtjvYLB0Ir0XCrYanEITl_zN0Mi843zsc-29ZschirbU2ywbzexHBjVumPAaZAVsDGhOOnhJzuBo-96QI637Y2-jSg4VowzrmU5Yge_Yeu05DH1-wozTlIrnbUySPlckLMfvncBpjZKTSjQvNX4ch-eln_mfznTDwAUqqV5A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2882215264</pqid></control><display><type>article</type><title>Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Venuto, Charles S ; Smith, Greta ; Herbst, Konnor ; Zielinski, Robert ; Yung, Norman C W ; Grosset, Donald G ; Dorsey, E Ray ; Kieburtz, Karl</creator><creatorcontrib>Venuto, Charles S ; Smith, Greta ; Herbst, Konnor ; Zielinski, Robert ; Yung, Norman C W ; Grosset, Donald G ; Dorsey, E Ray ; Kieburtz, Karl</creatorcontrib><description>In Parkinson's disease (PD), gait and balance is impaired, relatively resistant to available treatment and associated with falls and disability. Predictive models of ambulatory progression could enhance understanding of gait/balance disturbances and aid in trial design. To predict trajectories of ambulatory abilities from baseline clinical data in early PD, relate trajectories to clinical milestones, compare biomarkers, and evaluate trajectories for enrichment of clinical trials. Data from two multicenter, longitudinal, observational studies were used for model training (Tracking Parkinson's, n = 1598) and external testing (Parkinson's Progression Markers Initiative, n = 407). Models were trained and validated to predict individuals as having a "Progressive" or "Stable" trajectory based on changes of ambulatory capacity scores from the Movement Disorders Society Unified Parkinson's Disease Rating Scale parts II and III. Survival analyses compared time-to-clinical milestones and trial outcomes between predicted trajectories. On external evaluation, a support vector machine model predicted Progressive trajectories using baseline clinical data with an accuracy, weighted-F1 (proportionally weighted harmonic mean of precision and sensitivity), and sensitivity/specificity of 0.735, 0.799, and 0.688/0.739, respectively. Over 4 years, the predicted Progressive trajectory was more likely to experience impaired balance, loss of independence, impaired function and cognition. Baseline dopamine transporter imaging and select biomarkers of neurodegeneration were significantly different between predicted trajectory groups. For an 18-month, randomized (1:1) clinical trial, sample size savings up to 30% were possible when enrollment was enriched for the Progressive trajectory versus no enrichment. It is possible to predict ambulatory abilities from clinical data that are associated with meaningful outcomes in people with early PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</description><identifier>ISSN: 0885-3185</identifier><identifier>ISSN: 1531-8257</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.29519</identifier><identifier>PMID: 37363815</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Balance ; Biomarkers ; Clinical trials ; Cognition ; Disease Progression ; Dopamine transporter ; Gait ; Humans ; Mental Status and Dementia Tests ; Movement disorders ; Neurodegeneration ; Neurodegenerative diseases ; Parkinson Disease - complications ; Parkinson's disease ; Physical Therapy Modalities ; Prediction models</subject><ispartof>Movement disorders, 2023-10, Vol.38 (10), p.1774-1785</ispartof><rights>2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c364t-d600520960c4a9121a1a6e925473266481c9541457e969519ebc13863d2a81f63</cites><orcidid>0000-0002-2394-9513</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37363815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Venuto, Charles S</creatorcontrib><creatorcontrib>Smith, Greta</creatorcontrib><creatorcontrib>Herbst, Konnor</creatorcontrib><creatorcontrib>Zielinski, Robert</creatorcontrib><creatorcontrib>Yung, Norman C W</creatorcontrib><creatorcontrib>Grosset, Donald G</creatorcontrib><creatorcontrib>Dorsey, E Ray</creatorcontrib><creatorcontrib>Kieburtz, Karl</creatorcontrib><title>Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design</title><title>Movement disorders</title><addtitle>Mov Disord</addtitle><description>In Parkinson's disease (PD), gait and balance is impaired, relatively resistant to available treatment and associated with falls and disability. Predictive models of ambulatory progression could enhance understanding of gait/balance disturbances and aid in trial design. To predict trajectories of ambulatory abilities from baseline clinical data in early PD, relate trajectories to clinical milestones, compare biomarkers, and evaluate trajectories for enrichment of clinical trials. Data from two multicenter, longitudinal, observational studies were used for model training (Tracking Parkinson's, n = 1598) and external testing (Parkinson's Progression Markers Initiative, n = 407). Models were trained and validated to predict individuals as having a "Progressive" or "Stable" trajectory based on changes of ambulatory capacity scores from the Movement Disorders Society Unified Parkinson's Disease Rating Scale parts II and III. Survival analyses compared time-to-clinical milestones and trial outcomes between predicted trajectories. On external evaluation, a support vector machine model predicted Progressive trajectories using baseline clinical data with an accuracy, weighted-F1 (proportionally weighted harmonic mean of precision and sensitivity), and sensitivity/specificity of 0.735, 0.799, and 0.688/0.739, respectively. Over 4 years, the predicted Progressive trajectory was more likely to experience impaired balance, loss of independence, impaired function and cognition. Baseline dopamine transporter imaging and select biomarkers of neurodegeneration were significantly different between predicted trajectory groups. For an 18-month, randomized (1:1) clinical trial, sample size savings up to 30% were possible when enrollment was enriched for the Progressive trajectory versus no enrichment. It is possible to predict ambulatory abilities from clinical data that are associated with meaningful outcomes in people with early PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</description><subject>Balance</subject><subject>Biomarkers</subject><subject>Clinical trials</subject><subject>Cognition</subject><subject>Disease Progression</subject><subject>Dopamine transporter</subject><subject>Gait</subject><subject>Humans</subject><subject>Mental Status and Dementia Tests</subject><subject>Movement disorders</subject><subject>Neurodegeneration</subject><subject>Neurodegenerative diseases</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson's disease</subject><subject>Physical Therapy Modalities</subject><subject>Prediction models</subject><issn>0885-3185</issn><issn>1531-8257</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1PGzEQhq2KqgTaQ_9AZYlDQWKpx157vScUQr8kpOZAz5bjdYLDrh08u5XCr2dTKIKe5jCPXr0zDyEfgZ0BY_xL1-AZryXUb8gEpIBCc1ntkQnTWhYCtNwnB4hrxgAkqHdkX1RCCQ1yQtbz7Jvg-hBXdNothtb2KW_pzG6sC_2WhkjnNt-GiCl-RnoZ0Fv0tE90Gm27vfd0ntMqe8SQ4im9CKkbcZ_xlNrY0OscbEsvPYZVfE_eLm2L_sPTPCS_v329nv0orn59_zmbXhVOqLIvGsWY5KxWzJW2Bg4WrPI1l2UluFKlBlfLEkpZ-VrtjvYLB0Ir0XCrYanEITl_zN0Mi843zsc-29ZschirbU2ywbzexHBjVumPAaZAVsDGhOOnhJzuBo-96QI637Y2-jSg4VowzrmU5Yge_Yeu05DH1-wozTlIrnbUySPlckLMfvncBpjZKTSjQvNX4ch-eln_mfznTDwAUqqV5A</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Venuto, Charles S</creator><creator>Smith, Greta</creator><creator>Herbst, Konnor</creator><creator>Zielinski, Robert</creator><creator>Yung, Norman C W</creator><creator>Grosset, Donald G</creator><creator>Dorsey, E Ray</creator><creator>Kieburtz, Karl</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2394-9513</orcidid></search><sort><creationdate>20231001</creationdate><title>Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design</title><author>Venuto, Charles S ; Smith, Greta ; Herbst, Konnor ; Zielinski, Robert ; Yung, Norman C W ; Grosset, Donald G ; Dorsey, E Ray ; Kieburtz, Karl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c364t-d600520960c4a9121a1a6e925473266481c9541457e969519ebc13863d2a81f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Balance</topic><topic>Biomarkers</topic><topic>Clinical trials</topic><topic>Cognition</topic><topic>Disease Progression</topic><topic>Dopamine transporter</topic><topic>Gait</topic><topic>Humans</topic><topic>Mental Status and Dementia Tests</topic><topic>Movement disorders</topic><topic>Neurodegeneration</topic><topic>Neurodegenerative diseases</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson's disease</topic><topic>Physical Therapy Modalities</topic><topic>Prediction models</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Venuto, Charles S</creatorcontrib><creatorcontrib>Smith, Greta</creatorcontrib><creatorcontrib>Herbst, Konnor</creatorcontrib><creatorcontrib>Zielinski, Robert</creatorcontrib><creatorcontrib>Yung, Norman C W</creatorcontrib><creatorcontrib>Grosset, Donald G</creatorcontrib><creatorcontrib>Dorsey, E Ray</creatorcontrib><creatorcontrib>Kieburtz, Karl</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Venuto, Charles S</au><au>Smith, Greta</au><au>Herbst, Konnor</au><au>Zielinski, Robert</au><au>Yung, Norman C W</au><au>Grosset, Donald G</au><au>Dorsey, E Ray</au><au>Kieburtz, Karl</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov Disord</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>38</volume><issue>10</issue><spage>1774</spage><epage>1785</epage><pages>1774-1785</pages><issn>0885-3185</issn><issn>1531-8257</issn><eissn>1531-8257</eissn><abstract>In Parkinson's disease (PD), gait and balance is impaired, relatively resistant to available treatment and associated with falls and disability. Predictive models of ambulatory progression could enhance understanding of gait/balance disturbances and aid in trial design. To predict trajectories of ambulatory abilities from baseline clinical data in early PD, relate trajectories to clinical milestones, compare biomarkers, and evaluate trajectories for enrichment of clinical trials. Data from two multicenter, longitudinal, observational studies were used for model training (Tracking Parkinson's, n = 1598) and external testing (Parkinson's Progression Markers Initiative, n = 407). Models were trained and validated to predict individuals as having a "Progressive" or "Stable" trajectory based on changes of ambulatory capacity scores from the Movement Disorders Society Unified Parkinson's Disease Rating Scale parts II and III. Survival analyses compared time-to-clinical milestones and trial outcomes between predicted trajectories. On external evaluation, a support vector machine model predicted Progressive trajectories using baseline clinical data with an accuracy, weighted-F1 (proportionally weighted harmonic mean of precision and sensitivity), and sensitivity/specificity of 0.735, 0.799, and 0.688/0.739, respectively. Over 4 years, the predicted Progressive trajectory was more likely to experience impaired balance, loss of independence, impaired function and cognition. Baseline dopamine transporter imaging and select biomarkers of neurodegeneration were significantly different between predicted trajectory groups. For an 18-month, randomized (1:1) clinical trial, sample size savings up to 30% were possible when enrollment was enriched for the Progressive trajectory versus no enrichment. It is possible to predict ambulatory abilities from clinical data that are associated with meaningful outcomes in people with early PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37363815</pmid><doi>10.1002/mds.29519</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2394-9513</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0885-3185
ispartof Movement disorders, 2023-10, Vol.38 (10), p.1774-1785
issn 0885-3185
1531-8257
1531-8257
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10615710
source MEDLINE; Wiley Journals
subjects Balance
Biomarkers
Clinical trials
Cognition
Disease Progression
Dopamine transporter
Gait
Humans
Mental Status and Dementia Tests
Movement disorders
Neurodegeneration
Neurodegenerative diseases
Parkinson Disease - complications
Parkinson's disease
Physical Therapy Modalities
Prediction models
title Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A05%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20Ambulatory%20Capacity%20in%20Parkinson's%20Disease%20to%20Analyze%20Progression,%20Biomarkers,%20and%20Trial%20Design&rft.jtitle=Movement%20disorders&rft.au=Venuto,%20Charles%20S&rft.date=2023-10-01&rft.volume=38&rft.issue=10&rft.spage=1774&rft.epage=1785&rft.pages=1774-1785&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.29519&rft_dat=%3Cproquest_pubme%3E2882215264%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2882215264&rft_id=info:pmid/37363815&rfr_iscdi=true